Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Systematic Review of Review Papers 2009-2011. An Update for Clinicians
Authors:
Open Access
- 1 January 2011
- journal article
- review article
- Published by SAGE Publications in Journal of Central Nervous System Disease
- Vol. 3, 209-17
Abstract
Attention deficit/hyperactivity disorder (ADHD) is a common disorder and a plethora of new data has been published from clinical trials and national epidemiological databases in the last three years. In the United Kingdom Atomoxetine is currently the only licensed non-stimulant medication. As part of a systematic review of atomoxetine data Jan 2009-June 2011 formal searches found 750 citations. From these 13 met criteria for either review or systematic review papers and contained clinical data synthesis on atomoxetine. No individual review paper alone would be sufficient for clinicians to be updated at that time on all clinical aspects of atomoxetine data. The crucial data relating to clinical parity of atomoxetine and methylphenidate in trials and meta-analysis where relevant confounding biases are removed are not often discussed. Systematic review of complex data is critical for ADHD clinicians and will need regular updating due to the large volume of new data.Keywords
This publication has 30 references indexed in Scilit:
- To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?European Neuropsychopharmacology, 2011
- Cardiovascular Events and Death in Children Exposed and Unexposed to ADHD AgentsPediatrics, 2011
- European guidelines on managing adverse effects of medication for ADHDEuropean Child & Adolescent Psychiatry, 2010
- Mortality Associated with Attention-Deficit Hyperactivity Disorder (ADHD) Drug TreatmentDrug Safety, 2009
- Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid ConditionsCNS Drugs, 2009
- Attention‐Deficit‐Hyperactivity Disorder: An UpdatePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- Review of ADHD Pharmacotherapies: Advantages, Disadvantages, and Clinical PearlsJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- Meta-Analysis of Suicide-Related Behavior Events in Patients Treated With AtomoxetineJournal of the American Academy of Child & Adolescent Psychiatry, 2008
- Comparing the efficacy of medications for ADHD using meta-analysis.2006
- Outcomes of OROS® methylphenidate compared with atomoxetine in children with ADHD: A multicenter, randomized prospective studyAdvances in Therapy, 2005